ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

VX-670

A development code.

Its studies are mostly in Myotonic Dystrophy, led by Vertex Pharmaceuticals.

Furthest: phase 2, since Dec 15, 20232 company-led studies, 2 open or runningNext primary completion: Feb 2, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals22 open or runningphase 2since Dec 15, 2023Dec 15, 2023Feb 2, 2027phase 2 · NCT06185764

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2023First study: phase 2 study in Myotonic DystrophyFirst studyNCT06185764 · 47 enrolled · United States, Australia, Belgium and more
  2. Apr 10, 2025Phase 2 study in Myotonic DystrophyNCT06926621 · 44 planned · United States, Australia, Belgium and more

Ahead

  1. Feb 2, 2027Primary completion: phase 2 study in Myotonic DystrophyNCT06185764
  2. Jan 30, 2029Primary completion: phase 2 study in Myotonic DystrophyNCT06926621

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06926621Myotonic Dystrophy · United States, Australia, Belgium and more2By invitationJan 30, 202944
NCT06185764Myotonic Dystrophy · United States, Australia, Belgium and more2Active, not recruitingFeb 2, 202747

How it is read

Names in the registry

  • “VX-670”, 2 entries

Codes read as this program: VX670.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.